K P Thompson1,2, J Nelson3, H Kim3,4,5, L Pawlikowska3,4, D A Marchuk6, M T Lawton7, Marie E Faughnan8,9. 1. Toronto HHT Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B-1W8, USA. 2. Division of Respirology, Department of Medicine, University of Toronto, Toronto, Canada. 3. Department of Anesthesia and Perioperative Care, Center for Cerebrovascular Research, University of California, San Francisco, CA, USA. 4. Institute for Human Genetics, University of California, San Francisco, CA, USA. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. 6. Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USA. 7. Barrow Neurological Institute, Phoenix, AZ, USA. 8. Toronto HHT Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B-1W8, USA. Marie.Faughnan@unityhealth.to. 9. Division of Respirology, Department of Medicine, University of Toronto, Toronto, Canada. Marie.Faughnan@unityhealth.to.
Abstract
BACKGROUND: Retrospective questionnaire and healthcare administrative data suggest reduced life expectancy in untreated hereditary hemorrhagic telangiectasia (HHT). Prospective data suggests similar mortality, to the general population, in Denmark's centre-treated HHT patients. However, clinical phenotypes vary widely in HHT, likely affecting mortality. We aimed to measure predictors of mortality among centre-treated HHT patients. HHT patients were recruited at 14 HHT centres of the Brain Vascular Malformation Consortium (BVMC) since 2010 and followed annually. Vital status, organ vascular malformations (VMs) and clinical symptoms data were collected at baseline and during follow-up (N = 1286). We tested whether organ VMs, HHT symptoms and HHT genes were associated with increased mortality using Cox regression analysis, adjusting for patient age, sex, and smoking status. RESULTS: 59 deaths occurred over average follow-up time of 3.4 years (max 8.6 years). A history of anemia was associated with increased mortality (HR = 2.93, 95% CI 1.37-6.26, p = 0.006), as were gastro-intestinal (GI) bleeding (HR = 2.63, 95% CI 1.46-4.74, p = 0.001), and symptomatic liver VMs (HR = 2.10, 95% CI 1.15-3.84, p = 0.015). Brain VMs and pulmonary arteriovenous malformations (AVMs) were not associated with mortality (p > 0.05). Patients with SMAD4 mutation had significantly higher mortality (HR = 18.36, 95% CI 5.60-60.20, p < 0.001) compared to patients with ACVRL1 or ENG mutation, but this estimate is imprecise given the rarity of SMAD4 patients (n = 33, 4 deaths). CONCLUSIONS: Chronic GI bleeding, anemia and symptomatic liver VMs are associated with increased mortality in HHT patients, independent of age, and in keeping with the limited treatment options for these aspects of HHT. Conversely, mortality does not appear to be associated with pulmonary AVMs or brain VMs, for which patients are routinely screened and treated preventatively at HHT Centres. This demonstrates the need for development of new therapies to treat chronic anemia, GI bleeding, and symptomatic liver VMs in order to reduce mortality among HHT patients.
BACKGROUND: Retrospective questionnaire and healthcare administrative data suggest reduced life expectancy in untreated hereditary hemorrhagic telangiectasia (HHT). Prospective data suggests similar mortality, to the general population, in Denmark's centre-treated HHTpatients. However, clinical phenotypes vary widely in HHT, likely affecting mortality. We aimed to measure predictors of mortality among centre-treated HHTpatients. HHTpatients were recruited at 14 HHT centres of the Brain Vascular Malformation Consortium (BVMC) since 2010 and followed annually. Vital status, organ vascular malformations (VMs) and clinical symptoms data were collected at baseline and during follow-up (N = 1286). We tested whether organ VMs, HHT symptoms and HHT genes were associated with increased mortality using Cox regression analysis, adjusting for patient age, sex, and smoking status. RESULTS: 59 deaths occurred over average follow-up time of 3.4 years (max 8.6 years). A history of anemia was associated with increased mortality (HR = 2.93, 95% CI 1.37-6.26, p = 0.006), as were gastro-intestinal (GI) bleeding (HR = 2.63, 95% CI 1.46-4.74, p = 0.001), and symptomatic liver VMs (HR = 2.10, 95% CI 1.15-3.84, p = 0.015). Brain VMs and pulmonary arteriovenous malformations (AVMs) were not associated with mortality (p > 0.05). Patients with SMAD4 mutation had significantly higher mortality (HR = 18.36, 95% CI 5.60-60.20, p < 0.001) compared to patients with ACVRL1 or ENG mutation, but this estimate is imprecise given the rarity of SMAD4patients (n = 33, 4 deaths). CONCLUSIONS:Chronic GI bleeding, anemia and symptomatic liver VMs are associated with increased mortality in HHTpatients, independent of age, and in keeping with the limited treatment options for these aspects of HHT. Conversely, mortality does not appear to be associated with pulmonary AVMs or brain VMs, for which patients are routinely screened and treated preventatively at HHT Centres. This demonstrates the need for development of new therapies to treat chronic anemia, GI bleeding, and symptomatic liver VMs in order to reduce mortality among HHTpatients.
Authors: Takeo Nishida; Marie E Faughnan; Timo Krings; Murali Chakinala; James R Gossage; William L Young; Helen Kim; Tony Pourmohamad; Katharine J Henderson; Stacy D Schrum; Melissa James; Nancy Quinnine; Aditya Bharatha; Karel G Terbrugge; Robert I White Journal: Am J Med Genet A Date: 2012-09-18 Impact factor: 2.802
Authors: Jan Lerut; Giuseppe Orlando; René Adam; Carlo Sabbà; Robert Pfitzmann; Jurgen Klempnauer; Jacques Belghiti; Jacques Pirenne; Thierry Thevenot; Christian Hillert; Colin M Brown; Dominique Gonze; Vincent Karam; Olivier Boillot Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Vivek N Iyer; Waleed Brinjikji; Bibek S Pannu; Dinesh R Apala; Giuseppe Lanzino; Harry J Cloft; Sanjay Misra; Michael J Krowka; Christopher P Wood; Karen L Swanson Journal: Mayo Clin Proc Date: 2016-11-01 Impact factor: 7.616
Authors: Marie E Faughnan; James R Gossage; Murali M Chakinala; S Paul Oh; Raj Kasthuri; Christopher C W Hughes; Justin P McWilliams; Joseph G Parambil; Nicholas Vozoris; Jill Donaldson; Gitanjali Paul; Pamela Berry; Dennis L Sprecher Journal: Angiogenesis Date: 2018-09-06 Impact factor: 9.596
Authors: K P Thompson; J Nelson; H Kim; S M Weinsheimer; D A Marchuk; M T Lawton; T Krings; M E Faughnan Journal: Orphanet J Rare Dis Date: 2021-09-19 Impact factor: 4.123
Authors: Mariana Floria; Elena Diana Năfureanu; Diana-Elena Iov; Oana Sîrbu; Mihaela Dranga; Anca Ouatu; Daniela Maria Tănase; Oana Bogdana Bărboi; Vasile Liviu Drug; Mihail Dan Cobzeanu Journal: J Clin Med Date: 2022-05-07 Impact factor: 4.241